Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ibsa Institut Biochimique SA has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners. This distribution shows that each pending matter is being reviewed independently by different personnel.
KIM, SEONG JONG is the busiest examiner for this portfolio, managing 1 pending office action. The prosecution also involves distinct art units. This requires a strategy that accounts for the individual preferences of different examiners across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18944936 | High-Stability Packaged Solutions of T4 Thyroid Hormone | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568590 | USE OF THYROID HORMONE T4 IN A HIGH VERSATILITY TREATMENT IN PATIENTS TAKING PROTON PUMP INHIBITORS | MCMILLIAN, KARA RENITA | 42d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18944936 | High-Stability Packaged Solutions of T4 Thyroid Hormone | KIM, SEONG JONG | 1621 | §103Other | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18568590 | USE OF THYROID HORMONE T4 IN A HIGH VERSATILITY TREATMENT IN PATIENTS TAKING PROTON PUMP INHIBITORS | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | 42d | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIbsa Institut Biochimique SA has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Seong Jong Kim has the most, with 1 of Ibsa Institut Biochimique SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
